Moving microfluidics ahead: Extending capabilities, accessibility, and applications

Paul Blainey is professor of Biological Engineering at MIT. In this contribution he describes three microfluidic technologies that he and his team has developed to extend the capability, accessibility, and applications of microfluidics: (1) Integrated microfluidic sample preparation for genomic assays, (2) hydrogel-based microfluidics for single-cell genome sequencing, and (3) an emulsion-based system for combinatorial drug screening.

💡 Research Summary

In this paper, Paul Blainey and his team at MIT and the Broad Institute present three distinct microfluidic platforms that together address major bottlenecks in genomic analysis, single‑cell sequencing, and combinatorial drug discovery. The first platform is an integrated, two‑layer microfluidic “lab‑on‑a‑chip” that consolidates all steps of next‑generation sequencing (NGS) library preparation—cell lysis, DNA extraction, SPRI bead purification, and library construction—into a single device the size of a business card. Using 36 nanoliter rotary reactors, standard hydraulic micro‑valves, and novel filter valves, the system can process up to 96 samples in parallel, reduce input DNA requirements by more than 100‑fold, achieve >80 % DNA recovery, and dramatically cut reagent consumption and hands‑on time. By enabling direct translation of conventional bench‑top protocols to the microscale, this device promises to make NGS‑based diagnostics feasible for low‑biomass clinical specimens.

The second platform introduces “virtual microfluidics,” a hydrogel‑based compartmentalization strategy that eliminates the need for physical channels. A cross‑linked poly(ethylene glycol) (PEG) hydrogel is functionalized to trap single cells or DNA molecules, then lysed in situ by enzymatic and heat treatment. Multiple displacement amplification (MDA) proceeds within the gel matrix, where restricted diffusion suppresses cross‑priming and reduces chimeric reads to ~0.5 %—about five times lower than conventional liquid‑based MDA. Single‑cell whole‑genome sequencing of Escherichia coli and Staphylococcus aureus yields 30 % and 60 % genome coverage respectively, with uniformity comparable to published datasets. The transparent hydrogel also permits real‑time fluorescence labeling, making the approach compatible with downstream in‑situ assays and multiplexed omics.

The third platform tackles the combinatorial explosion inherent in drug‑pair screening by leveraging droplet emulsions combined with optical barcoding and electric‑field‑mediated droplet pairing. Each 1 nL aqueous droplet encapsulates a library compound and an RGB optical barcode; droplets are pooled, arrayed in a 50 000‑well silicone chip, and paired via an applied electric field. After a 7‑hour bacterial growth assay (Pseudomonas aeruginosa), fluorescence readout quantifies inhibition for each compound pair. The system screened 1800 pairwise combinations of 60 drugs in a single run, achieving Z′ > 0.5 and R² > 0.95, while consuming less than 1 % of the reagent volumes required by standard plate‑based screens. Crucially, the method requires only a commodity microscope and an emulsifier, eliminating the need for expensive robotics.

Collectively, these three technologies demonstrate a coherent strategy to expand microfluidics’ capabilities (high‑throughput, low‑input, high‑fidelity processing), improve accessibility (standardized components, minimal specialized equipment), and broaden applications (clinical genomics, single‑cell biology, high‑dimensional drug discovery). By integrating sample preparation, virtual compartmentalization, and scalable emulsion assays, Blainey’s group provides a versatile toolkit that could accelerate precision medicine, microbial genomics, and therapeutic development.